Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.

BenzingaApr 10 01:12

Inozyme Pharma Is Maintained at Buy by B of A Securities

Inozyme Pharma Is Maintained at Buy by B of A Securities

Dow JonesApr 10 00:47

B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma with a Buy and lowers the price target from $16 to $14.

Analyst UpgradesApr 10 00:38

Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.

Needham: Reiterates Inozyme Pharma (INZY.US) rating and adjusted from buy to buy rating, target price of $23.00.

Zhitong FinanceApr 9 20:02

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Needham analyst Joseph Stringer reiterates Inozyme Pharma with a Buy and maintains $23 price target.

Analyst UpgradesApr 9 19:56

Inozyme Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 298.61% Needham → $23 Reiterates Buy → Buy 03/13/2024 177.3% HC Wainwright & Co. $16 → $16 Main

BenzingaApr 9 19:53